IL6 and COVID-19: In a preliminary clinical trial [67], patients with COVID-19 who were administered liposome-encapsulated bLf orally (1 g/day) and intranasally (16 mg/day) had significantly lower levels of IL-6 and D-dimers, considered therapeutic targets in COVID-19; they also exhibited significantly faster SARS-CoV-2 RNA negative conversion in comparison to controls receiving standard treatment with hydroxychloroquine and lopinavir/darunavir alone [152,153].